Critical Reviews in Oncology / Hematology
Volume 73, Issue 1 , Pages 23-30, January 2010

Pegylated liposomal doxorubicin combined with carboplatin: A rational treatment choice for advanced ovarian cancer

  • Sandro Pignata

      Affiliations

    • Medical Oncology, National Cancer Institute, Naples, Italy
    • Corresponding Author InformationCorresponding author at: Instituto Nazionale Tumori de Napoli, Dipartimento Uro-Ginecologico, UOC Oncologia Medica, via M Semmola, Naples, 80131, Italy. Tel.: +39 081 5903637; fax: +39 081 5903861.
    • ,
  • Eric Pujade Lauraine

      Affiliations

    • Medical Oncology, Paris Descartes, AP-HP, Hôtel-Dieu, Paris, France
    • ,
  • Andreas du Bois

      Affiliations

    • Gynecology and Gynecologic Oncology, HSK, Dr. Horst Schmidt Klinik, Wiesbaden, Germany
    • ,
  • Carmela Pisano

      Affiliations

    • Medical Oncology, National Cancer Institute, Naples, Italy

published online 27 September 2009.

Abstract 

Objective

Many questions remain unanswered regarding the optimal treatment paradigm for ovarian cancer, and alternatives for both first- and second-line therapy are needed.

Methods

This review summarizes recent data with the combination of pegylated liposomal doxorubicin (PLD) and carboplatin in ovarian cancer.

Results

Anthracyclines are active in ovarian cancer and lack the neurotoxic effects of taxanes. PLD has reduced cardiotoxic potential vs non-liposomal doxorubicin and is the only non-platinum monotherapy to demonstrate a significant survival advantage as second-line treatment of ovarian cancer. Replacing the taxane with PLD in platinum doublets for either first-line or recurrent ovarian cancer (ROC) has been or is being evaluated in more than 1600 patients. Studies evaluating PLD plus carboplatin in platinum-sensitive ROC have shown that the regimen is tolerable and active.

Conclusion

PLD–carboplatin is a promising chemotherapy combination. Phase III trials will elucidate whether it represents a new standard of care in ovarian cancer.

Keywords: Pegylated liposomal doxorubicin, Carboplatin, Platinum, Chemotherapy, Anthracycline, Ovarian cancer, Recurrent, Advanced disease

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S1040-8428(09)00176-0

doi:10.1016/j.critrevonc.2009.08.004

Refers to corrigendum:

  • Corrigendum to “Pegylated liposomal doxorubicin combined with carboplatin: A rational treatment choice for advanced ovarian cancer” [Crit. Rev. Oncol./Hematol. 73 (2010) 23–30]

    Sandro Pignata, Eric Pujade Lauraine, Andreas du Bois, Carmela Pisano
    Critical Reviews in Oncology / Hematology June 2010 (Vol. 74, Issue 3, Page 225)

Critical Reviews in Oncology / Hematology
Volume 73, Issue 1 , Pages 23-30, January 2010

Article Tools

* Image Usage & Resolution